A newly identified SARS-CoV-2 variant, BA32, is spreading globally with mutations that may reduce vaccine and prior infection protection, underscoring the continued importance of genomic surveillance.
A newly identified SARS-CoV-2 variant, BA32, is drawing increased attention from global public health officials as it spreads across multiple continents and demonstrates a notable ability to evade immune defenses. First detected in South Africa in November 2024, BA32 has since been identified in at least 23 countries and continues to appear in both international travelers and domestic surveillance systems in the United States.
The findings were published in last week’s Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report.
BA32 is a descendant of earlier Omicron sublineages but stands out due to its extensive mutations—particularly in the spike protein, the part of the virus targeted by most vaccines and immune responses. Compared with the JN1 lineage and its descendant LP81 (used in the 2025–2026 COVID-19 vaccines), BA32 carries approximately 70–75 genetic changes in the spike protein. These include significant alterations in both the receptor-binding domain and N-terminal domain, regions critical for viral entry and immune recognition.
Laboratory analyses suggest that these mutations may enable BA32 to partially evade antibodies generated by prior infection or vaccination. Early studies indicate that neutralizing antibody responses to BA32 are lower than for other circulating variants, raising concerns about reduced vaccine effectiveness. However, real-world data on disease severity and vaccine performance against this variant remain limited.
Despite these immune escape characteristics, BA32 has not yet demonstrated the rapid dominance seen with earlier variants like Omicron. Instead, it has co-circulated alongside other variants, particularly in parts of Europe where it has reached prevalence levels of 10% to 40% in some countries. Importantly, overall COVID-19 incidence in these regions has not surged dramatically, suggesting that BA32 may not currently drive large increases in cases.
One possible explanation lies in the variant’s biological behavior. Laboratory studies have found that BA32 may have reduced ability to bind to ACE2 receptors and enter lung cells compared with other variants. This could limit its transmissibility or competitiveness, even as it evades immune responses. However, scientists caution that further mutations could enhance these properties over time.
In the United States, BA32 was first detected in June 2025 through a traveler-based surveillance program and later identified in clinical samples beginning in late 2025. As of early 2026, the variant remains relatively rare in clinical sequencing data, accounting for less than 1% of analyzed samples. However, its presence has been more widely detected through wastewater surveillance, with hundreds of positive samples identified across dozens of states.
This discrepancy highlights the growing importance of wastewater monitoring as an early warning system. In many cases, BA32 was detected in wastewater weeks before it appeared in patient samples, allowing public health officials to track its spread even as clinical sequencing has declined in recent years.
BA32 carries extensive spike protein mutations that may reduce protection from vaccines and prior infections.
The variant is spreading globally but has not yet become dominant, likely due to biological constraints on transmissibility.
Wastewater and genomic surveillance remain essential tools for early detection and monitoring of emerging SARS-CoV-2 variants.
The emergence of BA32 also reflects broader trends in SARS-CoV-2 evolution. Since the start of the pandemic, successive variants have developed mutations that enhance transmissibility or immune escape, prompting periodic updates to vaccine formulations. While BA32 has not yet triggered a major shift in variant dominance, its genetic profile suggests it could play a role in future waves of infection.
Public health experts emphasize that continued genomic surveillance—combining clinical sequencing, traveler monitoring, and wastewater analysis—is critical to understanding how BA32 and other variants evolve. These systems help identify emerging threats, guide vaccine updates, and inform public health responses.
Although widespread immunity from vaccination and prior infection has reduced severe outcomes overall, COVID-19 continues to cause substantial illness and death globally. The emergence of variants like BA32 serves as a reminder that the virus remains dynamic, and vigilance is still required to mitigate its impact.
